Transcripta Bio
PrivateLast Round
Early Funding
Jul 22, 2026
Total Funding Raised
$26.71M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Transcripta Bio is a biotechnology company that utilizes AI and high-resolution transcriptomic data to accelerate drug discovery and therapeutic development.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Healthcare Analytics, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Transcripta Bio Comparables
Compare Transcripta Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tahoe Therapeutics | 87% | |
| Arpeggio Biosciences | 85% | |
| Pepper Bio | 84% |
Transcripta Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jul 22, 2026 | ||||
| VC Round | Apr 29, 2024 | ||||
| Series A | Nov 5, 2021 | ||||
| Grant | Oct 1, 2021 | ||||
| Seed | Nov 23, 2020 | ||||
Seed | Oct 12, 2020 |
Key People
Founding team and executive leadership
Transcripta Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Prototype Capital | Seed |
| BlueYard Capital | Early Funding, Series A, VC Round, Seed |
| Gaingels | VC Round |
| JAZZ Venture Partners | Early Funding, Series A, VC Round, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 1306% MoM, from 80 to 1.1K.
- Jul 22, 2026
$24M raised with participation from BlueYard Capital and Mayo Clinic.
Recent news
Latest coverage and updates
- is_developingOct 9, 2026
Transcripta Bio, Inc. and Synfini Inc. develop a validated-quality lead candidate targeting MSH3 for potential Huntington’s disease treatment through an AI-driven collaboration that reaches the milestone within weeks.
- is_developingOct 9, 2026
Transcripta Bio, Inc. and Synfini develop a validated-quality MSH3-targeting lead candidate for Huntington's disease in weeks by combining transcriptomic analysis, AI-powered molecular design, and automated chemistry.
- partners_withOct 8, 2026
Transcripta Bio, Inc. and Synfini, Inc. announce results from a research collaboration that produces a validated lead candidate directed at MSH3 on Oct 8th '26.
Transcripta Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Transcripta Bio's valuation, stock price, and market status.
Is Transcripta Bio a public or private company?
Transcripta Bio is a private company.
What is the current stock price of Transcripta Bio?
Transcripta Bio is a private company, so its shares have no public market price. Caplight tracks Transcripta Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Transcripta Bio worth (valuation)?
Valuation information for Transcripta Bio is not publicly available.
Can I buy Transcripta Bio stock?
Transcripta Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Transcripta Bio's last funding round?
Transcripta Bio's most recent funding round was Early Funding on July 22, 2026.
Who are the main investors in Transcripta Bio?
Key investors in Transcripta Bio include BlueYard Capital.
Will Transcripta Bio IPO soon?
No public IPO plans have been announced for Transcripta Bio.
How can I track Transcripta Bio secondary market activity?
Caplight tracks bids, offers, and trades in Transcripta Bio's shares on secondary markets.